Arlene Weintraub

Arlene Weintraub
Arlene Weintraub
Contributing Writer

Arlene Weintraub has over 15 years of experience writing about health care, pharmaceuticals and biotechnology. Her freelance pieces have been published in the New York Times, US News & World Report, Technology Review, Scientific American, USA Today, Entrepreneur.com, FierceMarkets and other media outlets. She was previously a senior health writer for BusinessWeek, covering both the science and business of health. She also worked as an editor for Xconomy.com, covering the biotech industry, as well as technology, life sciences and clean technology companies. She has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the antiaging industry, Selling the Fountain of Youth, was published by Basic Books in 2010.

Stories by Arlene Weintraub

Thermo nears Life Tech merger with $1.1B sale to GE

Thermo Fisher reached a major milestone in its $13.6 billion bid to buy Life Technologies, announcing that it will sell its gene modulation, cell culture and magnetic beads segments to GE Healthcare for $1.06 billion. Thermo inked the deal after the European Commission said in November it would only approve the Life Tech merger if Thermo sold off some businesses.

Quidel entices investors with an FDA thumbs-up for its strep test

San Diego-based diagnostics maker Quidel has seen its stock gain 6% to $29.50 since December 30, when it announced that it received FDA clearance for its AmpliVue Group B Strep (GBS) assay, a handheld test that health workers can use to rapidly detect the disease. Now some analysts are predicting the company could see even more of a surge on strong demand for its rapid flu tests.

Carmat jumps on more good news for its artificial heart

One week after France's Carmat announced that the first patient treated in a trial of its artificial heart was doing well, hospital officials report that the patient's condition is still "very satisfactory," according to Reuters. Carmat's stock, which rose 27% to nearly $178.80 on the Paris exchange on Dec. 23, gained an additional 4% on twice its recent average daily trading volume on the news, Reuters reports.